Soligenix Inc. (SNGX) 1.8900 $SNGX
The Growth of The U.S Economy In the Second Quarter Fuels Small Cap Stocks
ACCESSWIRE - Thu Jun 25, 7:35AM CDT
CORAL GABLES, FL / ACCESSWIRE / June 25, 2015 / The U.S economy slightly fell in the first quarter of 2015 as it had a hard time with bad weather, a strong dollar, spending cuts in the energy sector and interruptions at West Coast ports. However in the second quarter the economy is showing growth and has rebounded thus far. A rebounding economy can equate to an uptrend in "Blue Chip" stocks, as more investors are willing to invest money in a bullish market. This growth also has ignited movement in small cap companies such as Soligenix, Inc. (OTCQB: SNGX), FBEC Worldwide Inc. (PINKSHEETS: FBEC) and Dominovas Energy Corp. (OTCQB: DNRG).
Soligenix Announces Publication of Successful Application of its Heat Stabilization Technology to a Human Papillomavirus Vaccine
PR Newswire - Tue Jun 02, 6:00AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today the publication of data demonstrating a heat stable vaccine formulation of a human papillomavirus (HPV) vaccine. The work was conducted at the University of Colorado, Boulder by Drs. Randolph and Garcea and demonstrated the successful conversion of a commercial virus-like particle (VLP) based vaccine requiring cold-chain storage to a subunit, alum-adjuvanted, vaccine which is stable at ambient temperatures. This work, funded by a University of Colorado Seed grant and the Specialized Program of Research Excellence (SPORE) in cervical cancer, is the first demonstration of the utility of Soligenix's ThermoVax(TM) technology, licensed from the University of Colorado, for the development of a subunit based commercial vaccine. ThermoVax(TM) has been previously demonstrated to enhance thermostability of both a ricin vaccine (RiVax(TM)) and an anthrax vaccine (VeloThrax(TM)), demonstrating stability of up to one year at 40 degrees Celsius (104 degrees Fahrenheit) or 16 weeks at 70 degrees Celsius (158 degrees Fahrenheit), respectively. In this work, the new HPV vaccine formulation was found to be stable for at least 12 weeks at 50 degrees Celsius (122 degrees Fahrenheit), consistent with previous findings. The results were published online in the European Journal of Pharmaceutics and Biopharmaceutics and are available at: http://www.sciencedirect.com/science/article/...1115002416.
XON: 46.54 (+1.02)
Soligenix Announces Collaboration with the University of Hawai'i at Manoa and Hawaii Biotech to Develop Heat Stable Ebola Vaccine
PR Newswire - Thu May 28, 6:00AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today a collaboration agreement with Axel Lehrer, PhD of the Department of Tropical Medicine, Medical Microbiology and Pharmacology, John A. Burns School of Medicine (JABSOM), University of Hawai'i at Manoa (UH Manoa ) and Hawaii Biotech, Inc. (HBI) to develop a heat stable subunit Ebola vaccine. Dr. Lehrer, a co-inventor of the Ebola vaccine with HBI, has shown proof of concept efficacy with subunit Ebola vaccines in non-human primates. Under the terms of the feasibility agreement, Soligenix will evaluate its proprietary vaccine thermostabilization technology, ThermoVax(TM), licensed from the University of Colorado, to stabilize components of the vaccine. Ultimately, the objective is to produce a thermostable Ebola vaccine for worldwide distribution that does not require cold storage. ThermoVax(TM) has been previously demonstrated to enhance thermostability of both ricin (RiVax(TM)) and anthrax (VeloThrax(TM)) subunit vaccines. The initial work on the potential Ebola vaccine will focus on a single protein subunit antigen.
XON: 46.54 (+1.02)
Exceptional Management, Disruptive Products Top The Checklist For Vista Partners' Ross Silver
Life Sciences Report - Seeking Alpha - Thu May 21, 8:48AM CDT
Investing in micro- and small-cap biotech companies carries great risk, but for investors who take the time to dig out the value proposition, the upside can be phenomenal. Enter Ross Silver of Vista Partners, who publishes research and owns many of...
XON: 46.54 (+1.02)
Vista Partners Updates Coverage on Soligenix, Inc. (Ticker: SNGX); Price Target $7.00
Marketwired - Thu May 21, 8:01AM CDT
Vista Partners announced today that it has updated coverage on Soligenix, Inc. ("The Company" or "SNGX"
(OTCBB: SNGX), a clinical stage biopharmaceutical company based in Princeton, New Jersey, and maintains its twelve-month price target of $7.00. Ross Silver, Principal Analyst at Vista Partners, stated, "The Company boasts a diverse pipeline with ten prospective drug candidates, including a Phase 3 ready asset slated to enter the clinic in 2015 and Phase 2 data due on SGX942, the Company's clinical candidate for the treatment of Oral Mucositis, due by the fourth quarter of 2015. Mucositis affects approximately 500,000 people in the US per year and occurs in 40% of patients receiving chemotherapy." Mr. Silver goes on to state, "The science behind the Company's prospective therapies has been and continues to be validated by a number of significant, important and influential entities such as government organizations and major pharmaceutical companies. The Company has been awarded numerous government grants and entered into strategic agreements with three companies including: Intrexon Corporation (NYSE: XON) ($4.5B mkt cap.), Emergent BioSolutions (NYSE: EBS) ($1.2B mkt cap.) & SciClone Pharmaceuticals (NASDAQ: SCLN) ($490M mkt cap.)." Mr. Silver concludes, "The Company has up to approximately $57 million in active government contracts and grant funding still available to support its associated research programs through 2018."
EBS: 33.85 (+1.10), XON: 46.54 (+1.02), SCLN: 9.02 (-0.52)
Soligenix Announces First Quarter 2015 Highlights and Financial Results
PR Newswire - Thu May 14, 6:00AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today recent highlights and financial results for the first quarter ended March 31, 2015.
XON: 46.54 (+1.02)
Soligenix inks development deal with Emergent BioSolutions for ricin vaccine
Seeking Alpha - at Seeking Alpha - Wed May 13, 9:54AM CDT
EBS: 33.85 (+1.10)
Vista Partners Publishes May 2015 Macroeconomic & Investment Newsletter
Marketwired - Wed May 13, 8:01AM CDT
Vista Partners ("Vista" has published its FREE Macroeconomic & Investment Monthly Newsletter for the month of May. Each monthly newsletter from Vista contains macroeconomic thoughts from Principal Analyst Ross Silver, investment considerations, monthly highlights of each covered company and other broad based commentary.
VUZI: 6.32 (+0.06), QQQ: 107.65 (+1.62), ONCS: 5.75 (-0.06)
Soligenix Announces Development Agreement with Emergent BioSolutions
PR Newswire - Wed May 13, 6:00AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that it has initiated a development agreement with Emergent BioSolutions to implement a commercially viable, scalable production technology for the RiVax(TM) drug substance protein antigen. RiVax(TM) is a vaccine candidate being developed to protect against ricin exposure. Soligenix will transfer the manufacturing processes and analytics to Emergent to conduct process development work that could potentially lead to a future commercial manufacturing collaboration.
EBS: 33.85 (+1.10), XON: 46.54 (+1.02)
Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO
PR Newswire - Mon May 04, 6:00AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that it will be presenting preclinical data from three of its biodefense programs at the upcoming Chemical and Biological Defense Science and Technology Conference on May 12-14, 2015 to be held at the America's Center Convention Complex at 701 Convention Plaza, St. Louis MO 63101.
XON: 46.54 (+1.02)
Soligenix Announces FDA Protocol Clearance of Pivotal Phase 3 Clinical Trial of SGX203 in Pediatric Crohn's Disease
PR Newswire - Tue Apr 14, 6:00AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that agreement has been reached with the US Food and Drug Administration (FDA) on the design of a pivotal, Phase 3 clinical trial evaluating its product, SGX203 (oral beclomethasone 17,21-dipropionate or BDP), in the treatment of pediatric Crohn's disease. SGX203 has previously been granted both orphan drug and fast track designations from the FDA for the treatment of Crohn's Disease in the pediatric population.
XON: 46.54 (+1.02)
Soligenix Inc.'s CEO Christopher Schaber Interviewed by The Life Sciences Report
Marketwired - Thu Apr 09, 8:15AM CDT
Orphan diseases associated with inflammation present excellent development opportunities for small biopharmaceutical companies and their investors. Additionally, inflammatory conditions can result from treatment with cancer therapeutics. The crossover between inflammation and oncology, coupled with vaccine programs of high strategic value, have allowed Soligenix Inc. (OTCQB: SNGX) to build a significant pipeline with substantial revenue potential. In this interview with The Life Sciences Report, Dr. Christopher J. Schaber, company President and CEO, outlines development programs targeting pediatric Crohn's disease, GI acute radiation syndrome, a rare lymphoma and the threat of ricin.
Vista Partners Publishes April 2015 Macroeconomic & Investment Newsletter
Marketwired - Wed Apr 08, 7:01AM CDT
Vista Partners ("Vista" has published its FREE Macroeconomic & Investment Monthly Newsletter for the month of April. Each monthly newsletter from Vista contains macroeconomic thoughts from Principal Analyst Ross Silver, investment considerations, monthly highlights of each covered company and other broad based commentary.
VUZI: 6.32 (+0.06), SYRX: 1.65 (+0.03), ONCS: 5.75 (-0.06)
Soligenix Announces Recent Accomplishments and Year-End 2014 Financial Results
PR Newswire - Tue Mar 24, 6:00AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today recent accomplishments and financial results for the year ended December 31, 2014.
XON: 46.54 (+1.02)
Soligenix Announces Publication of Successful Preclinical Efficacy and Immunogenicity Results for Ricin Toxin Vaccine
PR Newswire - Wed Mar 11, 6:00AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today the publication of data demonstrating complete protection and immunogenicity of its ricin vaccine, RiVax(TM), in preclinical studies, with analyses of previous human clinical samples. RiVax(TM) employs a derivative of recombinant ricin toxin A chain. The use of the Company's proprietary vaccine stabilization technology, ThermoVax(TM) has been previously demonstrated to enhance thermostability of RiVax(TM), enabling distribution without cold chain requirements. In this work, vaccination with RiVax(TM) provided 100% protection for non-human primates (NHPs) subsequently exposed to lethal doses of aerosolized ricin. Evaluation of antibodies produced by the NHPs after vaccination identified specific neutralizing antibodies which were also expressed by humans previously vaccinated with RiVax(TM). The results were published online in the Proceedings of the National Academy of Sciences and are available at the following link: http://www.pnas.org/content/early/2015/03/05/...f32229914c .
XON: 46.54 (+1.02)
Soligenix Announces Positive Recommendation by Data Review Committee on its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients
PR Newswire - Tue Mar 03, 6:00AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today it has received a positive recommendation from the Data Review Committee (DRC) to continue enrolling into the company's Phase 2 study evaluating SGX942, a first-in-class innate defense regulator (IDR), as a treatment for oral mucositis in patients undergoing chemoradiation (CRT) therapy for head and neck cancer. Following DRC review of available data on the subjects enrolled in the trial, the committee recommended that enrollment include an additional 20 subjects randomized into either a single SGX942 dose group or the placebo group to allow for a more targeted assessment of the drug's potential effect and to inform final dose selection in this patient population.
XON: 46.54 (+1.02)
Soligenix's SGX943 And SGX101 May Be A Solution For Melioidosis Treatment
Grant Zeng, CFA - Seeking Alpha - Wed Feb 18, 1:08PM CST
A recent news release from the US Centers for Disease Control and Prevention (CDC) on inquiry into melioidosis illness at Tulane National Research Center (TNPRC) has raised the visibility and awareness of melioidosis among healthcare...
XON: 46.54 (+1.02)
Ricin Toxin Vaccine Poster Presented at the 2015 ASM Biodefense and Emerging Diseases Research Meeting in Washington, DC
PR Newswire - Fri Feb 13, 6:00AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that it presented data from its recent preclinical study that demonstrated the efficacy and safety of its heat-stabilized ricin toxin vaccine (RiVax(TM)) in a non-human primate (NHP) lethal aerosolized ricin exposure model. The data was presented in a poster session at the American Society of Microbiology (ASM) Biodefense and Emerging Diseases Research meeting on Wednesday, February 11, 2015 at Washington Marriott Wardman Park, 2660 Woodley Rd. NW in Washington, DC.
XON: 46.54 (+1.02)
Preclinical Melioidosis Results Presented at the 2015 ASM Biodefense and Emerging Diseases Research Meeting in Washington, DC
PR Newswire - Wed Feb 11, 6:00AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that it presented data from its recent preclinical study that demonstrated statistically significant efficacy of SGX943 in a mouse model of acute, lethal pneumonic melioidosis. The data was presented in an oral presentation at the American Society of Microbiology (ASM) Biodefense and Emerging Diseases Research meeting on Tuesday, February 10, 2015 at Washington Marriott Wardman Park, 2660 Woodley Rd. NW in Washington, DC.
XON: 46.54 (+1.02)
Soligenix to Present at the 17th Annual BIO CEO & Investor Conference in New York City
PR Newswire - Thu Feb 05, 6:00AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late stage biopharmaceutical company committed to developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that its President and Chief Executive Officer, Christopher J. Schaber, PhD, will give a corporate presentation at the 17th Annual BIO CEO Investor Conference in New York City, on Tuesday, February 10, 2015 at 1:30 PM Eastern Standard Time (EST). The presentation will take place in the Conrad room at the Waldorf Astoria.
XON: 46.54 (+1.02)
The Growth of The U.S Economy In the Second Quarter Fuels Small Cap Stocks
ACCESSWIRE - Thu Jun 25, 7:35AM CDT
CORAL GABLES, FL / ACCESSWIRE / June 25, 2015 / The U.S economy slightly fell in the first quarter of 2015 as it had a hard time with bad weather, a strong dollar, spending cuts in the energy sector and interruptions at West Coast ports. However in the second quarter the economy is showing growth and has rebounded thus far. A rebounding economy can equate to an uptrend in "Blue Chip" stocks, as more investors are willing to invest money in a bullish market. This growth also has ignited movement in small cap companies such as Soligenix, Inc. (OTCQB: SNGX), FBEC Worldwide Inc. (PINKSHEETS: FBEC) and Dominovas Energy Corp. (OTCQB: DNRG).
Soligenix Announces Publication of Successful Application of its Heat Stabilization Technology to a Human Papillomavirus Vaccine
PR Newswire - Tue Jun 02, 6:00AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today the publication of data demonstrating a heat stable vaccine formulation of a human papillomavirus (HPV) vaccine. The work was conducted at the University of Colorado, Boulder by Drs. Randolph and Garcea and demonstrated the successful conversion of a commercial virus-like particle (VLP) based vaccine requiring cold-chain storage to a subunit, alum-adjuvanted, vaccine which is stable at ambient temperatures. This work, funded by a University of Colorado Seed grant and the Specialized Program of Research Excellence (SPORE) in cervical cancer, is the first demonstration of the utility of Soligenix's ThermoVax(TM) technology, licensed from the University of Colorado, for the development of a subunit based commercial vaccine. ThermoVax(TM) has been previously demonstrated to enhance thermostability of both a ricin vaccine (RiVax(TM)) and an anthrax vaccine (VeloThrax(TM)), demonstrating stability of up to one year at 40 degrees Celsius (104 degrees Fahrenheit) or 16 weeks at 70 degrees Celsius (158 degrees Fahrenheit), respectively. In this work, the new HPV vaccine formulation was found to be stable for at least 12 weeks at 50 degrees Celsius (122 degrees Fahrenheit), consistent with previous findings. The results were published online in the European Journal of Pharmaceutics and Biopharmaceutics and are available at: http://www.sciencedirect.com/science/article/...1115002416.
XON: 46.54 (+1.02)
Soligenix Announces Collaboration with the University of Hawai'i at Manoa and Hawaii Biotech to Develop Heat Stable Ebola Vaccine
PR Newswire - Thu May 28, 6:00AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today a collaboration agreement with Axel Lehrer, PhD of the Department of Tropical Medicine, Medical Microbiology and Pharmacology, John A. Burns School of Medicine (JABSOM), University of Hawai'i at Manoa (UH Manoa ) and Hawaii Biotech, Inc. (HBI) to develop a heat stable subunit Ebola vaccine. Dr. Lehrer, a co-inventor of the Ebola vaccine with HBI, has shown proof of concept efficacy with subunit Ebola vaccines in non-human primates. Under the terms of the feasibility agreement, Soligenix will evaluate its proprietary vaccine thermostabilization technology, ThermoVax(TM), licensed from the University of Colorado, to stabilize components of the vaccine. Ultimately, the objective is to produce a thermostable Ebola vaccine for worldwide distribution that does not require cold storage. ThermoVax(TM) has been previously demonstrated to enhance thermostability of both ricin (RiVax(TM)) and anthrax (VeloThrax(TM)) subunit vaccines. The initial work on the potential Ebola vaccine will focus on a single protein subunit antigen.
XON: 46.54 (+1.02)
Exceptional Management, Disruptive Products Top The Checklist For Vista Partners' Ross Silver
Life Sciences Report - Seeking Alpha - Thu May 21, 8:48AM CDT
Investing in micro- and small-cap biotech companies carries great risk, but for investors who take the time to dig out the value proposition, the upside can be phenomenal. Enter Ross Silver of Vista Partners, who publishes research and owns many of...
XON: 46.54 (+1.02)
Vista Partners Updates Coverage on Soligenix, Inc. (Ticker: SNGX); Price Target $7.00
Marketwired - Thu May 21, 8:01AM CDT
Vista Partners announced today that it has updated coverage on Soligenix, Inc. ("The Company" or "SNGX"
(OTCBB: SNGX), a clinical stage biopharmaceutical company based in Princeton, New Jersey, and maintains its twelve-month price target of $7.00. Ross Silver, Principal Analyst at Vista Partners, stated, "The Company boasts a diverse pipeline with ten prospective drug candidates, including a Phase 3 ready asset slated to enter the clinic in 2015 and Phase 2 data due on SGX942, the Company's clinical candidate for the treatment of Oral Mucositis, due by the fourth quarter of 2015. Mucositis affects approximately 500,000 people in the US per year and occurs in 40% of patients receiving chemotherapy." Mr. Silver goes on to state, "The science behind the Company's prospective therapies has been and continues to be validated by a number of significant, important and influential entities such as government organizations and major pharmaceutical companies. The Company has been awarded numerous government grants and entered into strategic agreements with three companies including: Intrexon Corporation (NYSE: XON) ($4.5B mkt cap.), Emergent BioSolutions (NYSE: EBS) ($1.2B mkt cap.) & SciClone Pharmaceuticals (NASDAQ: SCLN) ($490M mkt cap.)." Mr. Silver concludes, "The Company has up to approximately $57 million in active government contracts and grant funding still available to support its associated research programs through 2018." EBS: 33.85 (+1.10), XON: 46.54 (+1.02), SCLN: 9.02 (-0.52)
Soligenix Announces First Quarter 2015 Highlights and Financial Results
PR Newswire - Thu May 14, 6:00AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today recent highlights and financial results for the first quarter ended March 31, 2015.
XON: 46.54 (+1.02)
Soligenix inks development deal with Emergent BioSolutions for ricin vaccine
Seeking Alpha - at Seeking Alpha - Wed May 13, 9:54AM CDT
EBS: 33.85 (+1.10)
Vista Partners Publishes May 2015 Macroeconomic & Investment Newsletter
Marketwired - Wed May 13, 8:01AM CDT
Vista Partners ("Vista"
has published its FREE Macroeconomic & Investment Monthly Newsletter for the month of May. Each monthly newsletter from Vista contains macroeconomic thoughts from Principal Analyst Ross Silver, investment considerations, monthly highlights of each covered company and other broad based commentary. VUZI: 6.32 (+0.06), QQQ: 107.65 (+1.62), ONCS: 5.75 (-0.06)
Soligenix Announces Development Agreement with Emergent BioSolutions
PR Newswire - Wed May 13, 6:00AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that it has initiated a development agreement with Emergent BioSolutions to implement a commercially viable, scalable production technology for the RiVax(TM) drug substance protein antigen. RiVax(TM) is a vaccine candidate being developed to protect against ricin exposure. Soligenix will transfer the manufacturing processes and analytics to Emergent to conduct process development work that could potentially lead to a future commercial manufacturing collaboration.
EBS: 33.85 (+1.10), XON: 46.54 (+1.02)
Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO
PR Newswire - Mon May 04, 6:00AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that it will be presenting preclinical data from three of its biodefense programs at the upcoming Chemical and Biological Defense Science and Technology Conference on May 12-14, 2015 to be held at the America's Center Convention Complex at 701 Convention Plaza, St. Louis MO 63101.
XON: 46.54 (+1.02)
Soligenix Announces FDA Protocol Clearance of Pivotal Phase 3 Clinical Trial of SGX203 in Pediatric Crohn's Disease
PR Newswire - Tue Apr 14, 6:00AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that agreement has been reached with the US Food and Drug Administration (FDA) on the design of a pivotal, Phase 3 clinical trial evaluating its product, SGX203 (oral beclomethasone 17,21-dipropionate or BDP), in the treatment of pediatric Crohn's disease. SGX203 has previously been granted both orphan drug and fast track designations from the FDA for the treatment of Crohn's Disease in the pediatric population.
XON: 46.54 (+1.02)
Soligenix Inc.'s CEO Christopher Schaber Interviewed by The Life Sciences Report
Marketwired - Thu Apr 09, 8:15AM CDT
Orphan diseases associated with inflammation present excellent development opportunities for small biopharmaceutical companies and their investors. Additionally, inflammatory conditions can result from treatment with cancer therapeutics. The crossover between inflammation and oncology, coupled with vaccine programs of high strategic value, have allowed Soligenix Inc. (OTCQB: SNGX) to build a significant pipeline with substantial revenue potential. In this interview with The Life Sciences Report, Dr. Christopher J. Schaber, company President and CEO, outlines development programs targeting pediatric Crohn's disease, GI acute radiation syndrome, a rare lymphoma and the threat of ricin.
Vista Partners Publishes April 2015 Macroeconomic & Investment Newsletter
Marketwired - Wed Apr 08, 7:01AM CDT
Vista Partners ("Vista"
has published its FREE Macroeconomic & Investment Monthly Newsletter for the month of April. Each monthly newsletter from Vista contains macroeconomic thoughts from Principal Analyst Ross Silver, investment considerations, monthly highlights of each covered company and other broad based commentary. VUZI: 6.32 (+0.06), SYRX: 1.65 (+0.03), ONCS: 5.75 (-0.06)
Soligenix Announces Recent Accomplishments and Year-End 2014 Financial Results
PR Newswire - Tue Mar 24, 6:00AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today recent accomplishments and financial results for the year ended December 31, 2014.
XON: 46.54 (+1.02)
Soligenix Announces Publication of Successful Preclinical Efficacy and Immunogenicity Results for Ricin Toxin Vaccine
PR Newswire - Wed Mar 11, 6:00AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today the publication of data demonstrating complete protection and immunogenicity of its ricin vaccine, RiVax(TM), in preclinical studies, with analyses of previous human clinical samples. RiVax(TM) employs a derivative of recombinant ricin toxin A chain. The use of the Company's proprietary vaccine stabilization technology, ThermoVax(TM) has been previously demonstrated to enhance thermostability of RiVax(TM), enabling distribution without cold chain requirements. In this work, vaccination with RiVax(TM) provided 100% protection for non-human primates (NHPs) subsequently exposed to lethal doses of aerosolized ricin. Evaluation of antibodies produced by the NHPs after vaccination identified specific neutralizing antibodies which were also expressed by humans previously vaccinated with RiVax(TM). The results were published online in the Proceedings of the National Academy of Sciences and are available at the following link: http://www.pnas.org/content/early/2015/03/05/...f32229914c .
XON: 46.54 (+1.02)
Soligenix Announces Positive Recommendation by Data Review Committee on its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients
PR Newswire - Tue Mar 03, 6:00AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today it has received a positive recommendation from the Data Review Committee (DRC) to continue enrolling into the company's Phase 2 study evaluating SGX942, a first-in-class innate defense regulator (IDR), as a treatment for oral mucositis in patients undergoing chemoradiation (CRT) therapy for head and neck cancer. Following DRC review of available data on the subjects enrolled in the trial, the committee recommended that enrollment include an additional 20 subjects randomized into either a single SGX942 dose group or the placebo group to allow for a more targeted assessment of the drug's potential effect and to inform final dose selection in this patient population.
XON: 46.54 (+1.02)
Soligenix's SGX943 And SGX101 May Be A Solution For Melioidosis Treatment
Grant Zeng, CFA - Seeking Alpha - Wed Feb 18, 1:08PM CST
A recent news release from the US Centers for Disease Control and Prevention (CDC) on inquiry into melioidosis illness at Tulane National Research Center (TNPRC) has raised the visibility and awareness of melioidosis among healthcare...
XON: 46.54 (+1.02)
Ricin Toxin Vaccine Poster Presented at the 2015 ASM Biodefense and Emerging Diseases Research Meeting in Washington, DC
PR Newswire - Fri Feb 13, 6:00AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that it presented data from its recent preclinical study that demonstrated the efficacy and safety of its heat-stabilized ricin toxin vaccine (RiVax(TM)) in a non-human primate (NHP) lethal aerosolized ricin exposure model. The data was presented in a poster session at the American Society of Microbiology (ASM) Biodefense and Emerging Diseases Research meeting on Wednesday, February 11, 2015 at Washington Marriott Wardman Park, 2660 Woodley Rd. NW in Washington, DC.
XON: 46.54 (+1.02)
Preclinical Melioidosis Results Presented at the 2015 ASM Biodefense and Emerging Diseases Research Meeting in Washington, DC
PR Newswire - Wed Feb 11, 6:00AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that it presented data from its recent preclinical study that demonstrated statistically significant efficacy of SGX943 in a mouse model of acute, lethal pneumonic melioidosis. The data was presented in an oral presentation at the American Society of Microbiology (ASM) Biodefense and Emerging Diseases Research meeting on Tuesday, February 10, 2015 at Washington Marriott Wardman Park, 2660 Woodley Rd. NW in Washington, DC.
XON: 46.54 (+1.02)
Soligenix to Present at the 17th Annual BIO CEO & Investor Conference in New York City
PR Newswire - Thu Feb 05, 6:00AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late stage biopharmaceutical company committed to developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that its President and Chief Executive Officer, Christopher J. Schaber, PhD, will give a corporate presentation at the 17th Annual BIO CEO Investor Conference in New York City, on Tuesday, February 10, 2015 at 1:30 PM Eastern Standard Time (EST). The presentation will take place in the Conrad room at the Waldorf Astoria.
XON: 46.54 (+1.02)
